Purpose. An overview of hyponatremia is provided, including its pathophysiology, clinical manifestations, signs and symptoms, and treatment, particularly with arginine vasopressin (AVP)-receptor antagonists. Summary. Hyponatremia (generally defined as a serum sodium concentration of <135 meq/L) is one of the most common electrolyte disorders in hospitalized and clinic patients. It may be caused by a number of conditions, including infections, heart disease, surgery, malignancy, and medication use. Clinical signs and symptoms such as hallucinations, lethargy, weakness, bradycardia, respiratory depression, seizures, coma, and death have been reported. Conventional treatment consists of fluid restriction and administration of hypertonic saline and pharmacologic agents, such as demeclocycline, lithium carbonate, and urea. These treatment options are often of limited effectiveness or difficult for patients to tolerate. AVP promotes the reabsorption of water in the renal collecting ducts by activation of V 2 receptors, resulting in water retention and dilution of serum solutes. The AVP-receptor antagonists, conivaptan, lixivaptan, and tolvaptan, are being studied for the treatment of hyponatremia. Conivaptan has been shown in clinical trials to increase freewater excretion and safely normalize serum sodium concentrations in patients with hyponatremia and is well tolerated. Also in clinical trials, lixivaptan and tolvaptan have safely improved serum sodium concentrations in patients with hyponatremia. Conclusion. Hyponatremia is a serious health condition for which treatment should be carefully performed. As new agents for treating hyponatremia, AVPreceptor antagonists have demonstrated efficacy and safety in clinical trials and may serve as significant improvements in the current treatment options for managing this disorder.
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Index terms: Antimanic agents; Arginine vasopressin receptor antagonists; Conivaptan; Demeclocycline; Diuretics; Electrolytes; Hospitals; Hyponatremia; Lithium carbonate; Lixivaptan; Mechanism of action; Sodium chloride; Tetracyclines; Tolvaptan; Toxicity; Urea Am J Health-Syst Pharm. 2007; 64:253-65 R eported in up to 28% of patients undergoing acute hospital care and 21% of patients undergoing ambulatory care, 1 hyponatremia (generally defined as a serum sodium concentration of <135 meq/L) 2 is one of the most common electrolyte disorders in hospitalized and clinic patients. [3] [4] [5] [6] [7] Central nervous system (CNS)-related symptoms can occur when the serum sodium concentration falls below 120 meq/L. [8] [9] [10] Hyponatremia often develops as a consequence of elevated levels of the hormone arginine vasopressin (AVP), which suppresses the renal excretion of solute-free water. 11 AVP elevation occurs in a number of common clinical conditions among hospitalized patients, including heart failure, liver cirrhosis, neuroendocrine disorders, and trauma. 6 Hospitalized patients also develop hyponatremia as a result of excessive fluid absorption from surgical irrigation or from concomitant drug administration. 11 Severe hyponatremia (<120 mEq/L) can cause significant and permanent neurologic injury or death. 2, 11 In addition, hyponatremia is a significant risk factor for 60-day mortality in patients with chronic heart failure. [12] [13] [14] [15] One study of hospitalized patients with worsening heart failure showed that of the 256 patients who had hyponatremia (serum sodium concentration of ≤136 meq/L) at baseline, 16% died within 60 days compared with 7% of patients (n = 687) who did not have hyponatremia at baseline (p = 0.0001). 12 This article provides an overview of salt and water regulation, describes the pathophysiology of hyponatre-Serum sodium concentrations are maintained within narrow limits (135-146 meq/L) by several mechanisms. The most important are the glomerular fi ltration rate, which affects the number of sodium ions that pass from the glomerular capillaries into Bowman's capsule and the renal tubules, and the release of aldosterone by the adrenal glands, which increases the reabsorption of sodium by the distal nephron. 9 The renal reabsorption and elimination of water are illustrated in Figure 1 . 17 The movement of water across cell membranes in the kidneys is achieved by way of water channel proteins, or aquaporins. AVP docking in the AVP V 2 receptors along the collecting ducts causes phosphorylation of aquaporin 2 (AQP2), insertion of the water channel into the apical membrane, and increased osmotic permeability, leading to water reabsorption. 17, 18 AVP receptors. AVP is released from the posterior pituitary in response to decreases in circulating sodium osmolality (detected by hypothalamic osmoreceptors) or blood volume or pressure (detected by vascular baroreceptors). 9, 11, 19 The release of AVP into the plasma stimulates free-water reabsorption in the collecting tubules of the kidneys. 9 Upon activation, the AVP V 2 receptors stimulate the insertion of water-permeable channels construct- Figure 1 . The movement of water across cell membranes in the kidneys is achieved by way of aquaporins (AQPs). AQP1, predominately located in the apical and basolateral plasma membranes of the proximal tubule of the nephron and the descending thin limb of the loop of Henle, is responsible at these locations for osmotic water reabsorption promoting the formation of concentrated urine. AQP2, AQP3, and AQP4 are located in the principal cells of the kidney collecting duct. Still under study, AQP3 and AQP4 appear to be water channels in the basolateral plasma membrane in the cells of many organs, including the collecting ducts of the kidneys. However, AQP2 expression is the main target of vasopressin in regulating osmosis in the collecting duct. Arginine vasopressin (AVP) docking in the AVP V 2 receptors along the collecting ducts causes phosphorylation of AQP2, insertion of the water channel into the apical membrane, and increased osmotic permeability leading to water reabsorption. 17, 18 Adapted, with permission, from reference 17. ed from AQP2, through the apical membrane of the principal cells that line the renal collecting ducts. 9 In the collecting duct cell, AVP targets the AVP V 2 receptor, activating protein kinase by way of cyclic adenosine monophosphate (cAMP), and phosphorylates aquaporins that insert into the luminal cell membrane of the collecting duct. With aquaporins in place, large volumes of water are thereby reabsorbed from the tubular fluid, subsequently increasing body water, blood pressure, and blood volume ( Figure 2) . 17, 20, 21 When the plasma AVP concentration decreases once again, cell membranes become relatively impermeable to water. 20 Activation of V 2 receptors also stimulates the expression of epithelial sodium channels, which are primarily located in the distal nephron. The upregulation of epithelial sodium channels increases renal sodium reabsorption. 22 Abnormal activation of V 2 receptors and AQP2 channels can result in disorders of water balance. Downregulation of AQP2 channels has been observed in several animal model systems that produce polyuria, including lithium-induced diabetes insipidus, bilateral or unilateral ureter obstruction, and ischemia-induced renal failure. 17 Conversely, mutations of the V 2 receptor have been reported to cause excessive V 2 -receptor activation even in the absence of AVP release, resulting in chronic excessive fluid retention (hypernatremia) and sodium dilution (hyponatremia). 20 Another important member of the AVP-receptor family is the V 1a receptor. Found on vascular smooth muscle cells and platelets, the V 1a receptor helps regulate vascular tone. 23 V 1a receptors function through the phosphoinositol pathway and increase intracellular calcium, resulting in vasoconstriction and an increased force of cardiac muscle contractility (positive inotropy). Continued stimulation of V 1a receptors has been theorized to activate protein synthesis, leading to vascular and myocardial hypertrophy. [24] [25] [26] A new class of agents-the AVPreceptor antagonists-is being developed to block the effects of excessive AVP secretion and to promote excretion of solute-free water or aquaresis. One agent in this class, conivaptan, is approved for the treatment of euvolemic hyponatremia in hospitalized patients.
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Hypernatremia. Disorders of water balance may produce a wide range of effects on serum sodium, body fluid volume, fluid distribution, and AVP secretion. 2, 9, 11 Hypernatremia, generally a loss of body water in relation to body solutes, is a clinical condition marked by high levels of sodium in the blood and is most commonly the result of insuf- THERAPY UPDATE Hyponatremia fi cient water intake or excessive water excretion. 9 Hypernatremia can occur in a number of conditions that are associated with low AVP secretion or decreased AVP-receptor sensitivity (e.g., diabetes insipidus).
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Hyponatremia. Hyponatremia, an excess of body water relative to extracellular sodium, may be caused either by the excessive loss of sodium (depletional hyponatremia) or by the retention of excessive water (dilutional hyponatremia). 9 Depletional hyponatremia is usually associated with decreased ECF volume (hypovolemic hyponatremia), which may be caused by disorders or medications that produce excessive renal loss of salts (e.g., diuretic use or renal salt-wasting syndrome). Dilutional hyponatremia is associated with either elevated total ECF volume (hypervolemic hyponatremia) or essentially normal ECF volume (euvolemic hyponatremia). 9 Hypervolemic hyponatremia is usually caused by fluid overload associated with elevated AVP secretion, as in liver cirrhosis, renal disease, or congestive heart failure (CHF). Hypervolemic hyponatremia and the associated shifts in fl uid and solute concentration are summarized in Figure 3 . 5 Euvolemic hyponatremia is usually caused by the elevated release of AVP and is most commonly associated with the syndrome of inappropriate antidiuretic hormone (SIADH).
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Normal laboratory values. Normal physiological values for serum and urine sodium and osmolality and AVP levels are shown in Appendix A. 7, 29 Additionally, Appendix B lists the values associated with hyponatremia, specifi cally SIADH. 9, 30 Extracellular volume status may be assessed using several techniques, including body weight, urine or blood test, bioelectric impedance and conductance, and ultrasonography. 31 Fluid volume may also be assessed clinically using criteria such as a patient history of vomiting or diarrhea; a decrease in skin turgor or axillary moisture, dry mucous membranes, and thirst; weight loss (>0.5 kg); a decrease in orthostatic blood pressure (≥10%); an increase in orthostatic pulse rate (≥10%); or a ratio of blood urea nitrogen to creatinine of >20:1.
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Clinical manifestations of hyponatremia
Hyponatremia among hospitalized patients may be caused by a number of conditions, including infections, heart disease, surgery, malignancy, and medication use, 33 and is especially common among the hospitalized or institutionalized elderly. 1, 34 SIADH. As the most common cause of euvolemic hypoosmolality (plasma osmolality of <275 mOsm/kg water with inappropriate urine concentration), 9 SIADH is associated with many systemic disorders ( Table  1) . 6 With decreased plasma osmolality, patients fail to suppress AVP secretion, resulting in impaired free-water excretion leading to SIADH. 6 SIADH is characterized by hyponatremia, decreased serum osmolality, elevated urine sodium, concentrated urine, and normal TBW. CHF. Patients with CHF often develop increased AVP release as part of a compensatory mechanism by which the body attempts to counteract decreasing cardiac function the and reduced volume of effectively circulating blood. However, increasing fl uid volume makes it more difficult for the heart to effi ciently pump blood, which exacerbates CHF and stimulates the release of higher levels of AVP. 15, 35 There is some preclinical evidence that activation of V 1a receptors may also contribute to cardiac disease by producing vasoconstriction, increasing preload and afterload, and often leading to ventricular remodeling and hypertrophy. 35 Cirrhosis with ascites. In a study of 191 patients with cirrhosis, hyponatremia was present in approximately 30% of hospitalized patients and was associated with diuretic use, peritoneal bacterial infection from ascites, variceal bleeding, and renal failure. 36 Inpatient mortality was three times higher for cirrhotic patients with hyponatremia than for those with normal serum sodium levels at admission.
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Other causes of hyponatremia in acutely ill patients. Emergency department. Hyponatremia affects as many as 4-29% of patients in emergency departments. 38, 39 Patients frequently develop hypovolemic hyponatremia as a result of extrarenal sodium loss due to diarrhea and vomiting. 40 Neurologic injury. Brain injury (e.g., from trauma, subarachnoid hemorrhage, secondary to arteriovenous malformation or aneurysm, pituitary compression [e.g., secondary tumor or cyst]) is frequently associated with hyponatremia. 41, 42 A common occurrence following neurosurgery, 43 hyponatremia has been reported in as many as 21-39% of patients after transsphenoidal surgery of the pituitary region. 44, 45 The increased risk of hyponatremia after CNS-related surgery is thought to refl ect AVP release caused by damage (stretching or compression) to the posterior pituitary or the development of cerebral salt-wasting syndrome, a poorly understood disorder of accelerated renal salt excretion and volume depletion after brain injury. [45] [46] [47] Surgery. Hyponatremia has been reported in approximately 4% of patients undergoing general surgery 48 and is associated with positivepressure endotracheal ventilation. 28 Patients who undergo transurethral resection of the prostate for benign prostatic hyperplasia often develop hyponatremia as a consequence of irrigation with large volumes of sodium-free solutions that contain glycine, sorbitol, mannitol, or sterile water. 49 Hyponatremia has also been associated with the i.v. infusion of A is the normal state of body fluids with solute concentrations in equilibrium on either side of the cell membrane. B indicates the first phase of water retention as the kidneys fail to normalize fluid volume (antidiuresis). In this hypervolemic state, solutes are diluted and plasma sodium will be decreased to hyponatremic levels. C illustrates how the cells and ECF attempt to reach homeostasis. Volume regulatory mechanisms excrete potassium and water from the ICF and osmolytes and water from the ECF into the intravascular space. D shows that fluid volume is still expanded, and solutes having been extruded and metabolized are at low concentrations in both ICF and ECF (hypervolemic hyponatremia). E shows that even with body fluid adaptation, low solute concentration in the cells and ECF persists (euvolemic hyponatremia). ECF = extracellular fluid, ICF = intracellular fluid, S = solutes, VRD = compensatory volume regulated decreases to reduce effective solute content (includes pressure diuresis and natriuretic factors in ECF and stretch activated channels, osmolyte synthesis, and osmolyte uptake transport in ICF). Adapted, with permission, from reference 5.
hypotonic solutions during surgery. 50 The use of purgative solutions to evacuate the bowel before colorectal surgery or colonoscopy has been shown to produce electrolyte abnormalities, such as hyponatremia, in some patients. 51 Endocrine disorders. Endocrine disorders that are associated with hyponatremia include hypothyroidism 52, 53 and adrenal insufficiency. 54 Hyponatremia has also been reported in 38% of patients hospitalized with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex, either as a result of gastrointestinal fluid loss or SIADH, 55 and is associated with an increased duration of hospitalization and a decreased likelihood of survival in patients with human immunodeficiency virus (HIV) infection. 56 Cancer. In an 11-month study of hospitalized patients with cancer (n = 106), the incidence of hyponatremia was 3.7 per 100 hospitalizations; hyponatremia was most commonly attributed to electrolyte depletion from gastrointestinal or renal losses, diuretic use, or SIADH. 57 Medications. Hyponatremia has been linked to the use of numerous drugs. Thiazide diuretics stimulate
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fl uid loss, which causes a compensatory increase in AVP secretion and prevents the reabsorption of sodium by the distal tubules, resulting in urinary sodium loss. Loop diuretics produce this same effect but to a lesser extent. 58 Risk factors for hyponatremia with diuretic use include increasing patient age, lower body weight, and lower serum potassium. 59 Hyponatremia has been described with a number of selective serotonin-reuptake inhibitors and serotonin-and norepinephrinereuptake inhibitors, including fl uox- etine, citalopram, venlafaxine, sertraline, and paroxetine, especially during the fi rst few weeks of treatment. [60] [61] [62] [63] [64] [65] Anticonvulsants such as levetiracetam, carbamazepine, and oxcarbazepine have been reported to increase the risk of hyponatremia by increasing either the release of AVP or the sensitivity of AVP receptors. 66, 67 AVP secretion and hyponatremia have also been reported with cigarette smoking and, in a recent case report, with the use of nicotinereplacement therapy. 68 Case reports or retrospective studies have described hyponatremia in association with several other drugs, including the proton-pump inhibitor esomeprazole, 69 the synthetic AVP analogue desmopressin, 70 the amphetamine derivative methylenedioxymethamphetamine (MDMA), 71 and the antiarrhythmic drug amiodarone.
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Signs and symptoms of hyponatremia
The symptoms of hyponatremia usually begin to appear when the plasma sodium concentration falls below 120 meq/L, and these symptoms worsen with the increasing sodium defi cit and increased rate of sodium loss. 2, 10, 11 Initial symptoms may include headache, nausea, and vomiting. Clinical signs and symptoms such as hallucinations, lethargy, weakness, bradycardia, respiratory depression, seizures, coma, and death have been reported. 10 Hyponatremic encephalopathy and cerebral edema may eventually occur and can cause systemic hypoxia as a result of centrally mediated noncardiogenic pulmonary edema or acute hypercapnic respiratory failure. 73 However, these characteristic signs and symptoms of hyponatremia may in fact refl ect an underlying disorder. Hyponatremia is a diagnosis of exclusion and, for proper diagnosis, other conditions (e.g., hypothyroidism, hypocortisolism, diuretic use) must fi rst be ruled out. 9 Acute, severe hyponatremia has been associated with permanent brain damage and even death, and, in subjects who have had surgery and developed encephalopathy, the risk of death or permanent neurologic sequelae was found to be 25 times higher in premenopausal women than in men or postmenopausal women. 50 In a multivariate analysis of 168 hospitalized patients with hyponatremia, investigators reported that the predictors of shortterm mortality included hypoxia, sepsis, and the presence of hyponatremic symptomatology (Table 2) . 74 Without adequate treatment, acute hyponatremia is associated with significant morbidity and mortality. 74 The loss of sodium from the ECF creates an osmotic pressure gradient across cell membranes that tends to attract water from the extracellular space (low-solute concentration) to the intracellular space (high-solute concentration), creating cellular swelling. 2 This swelling is particularly injurious to brain cells because the cranium limits the ability of the brain tissue to expand. 2 Animal models suggest that hyponatremia following traumatic brain injury can cause significant secondary neurologic injury as a consequence of focal contusions and diffuse axonal injury caused from brain swelling or herniation. 75 Chronic, symptomatic hyponatremia is also associated with a number of adverse outcomes, including permanent neurologic injury and death. 76 During the course of chronic hyponatremia, the brain adapts to serum hypoosmolality and brain edema by expelling organic osmolytes and electrolytes past the blood-brain barrier. Because osmolytes readapt slowly (five to seven days) to the hyperosmolar state when chronic hyponatremia is corrected too rapidly, the patient may then be at risk for the development of osmotic demyelination syndrome (ODS), a disorder involving the destruction of the myelin sheath covering the axons in the brainstem and ultimately preventing interneuronal communication. 5, [77] [78] [79] When the pathogenesis of ODS was investigated retrospectively in 12 cases, an association was found between the rapid rise in serum sodium and ODS in patients with hyponatremia. 78 Even though this early retrospective investigation was not conclusive, subsequent studies in patients with chronic hyponatremia strongly linked rapid correction of serum sodium with ODS. [77] [78] [79] In most cases, a correction rate of <12 meq/L/day provides recovery from hyponatremia without neurologic complications. 80 Many of these changes in brain architecture are irreversible; thus, prevention is the key. Other medical conditions associated with ODS include chronic alcoholism, hepatic failure, potassium depletion, malnutrition, thiazide therapy, and liver transplantation. 2 Researchers are hopeful that further investigation of the transport mechanisms of organic osmolytes involving the brain may lead to an understanding of how to enhance readaptation during the correction of hyponatremia.
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Treatment options
Management of hyponatremia in hospitalized patients depends on the duration and magnitude of the hyponatremia. Acute hyponatremia develops in less than 48 hours. Severe hyponatremia is associated with neurologic symptoms and considered a medical emergency. 9, 11 Even though the initial goals in the management of hyponatremia are restoration of serum sodium and resolution of symptoms, the underlying causes of hyponatremia should be identified and corrected, if feasible. 81 For example, in cases of diureticinduced hyponatremia, a change or discontinuation of the diuretic agent may resolve the patient's hyponatremia. 58, 59, 82 In general, the management of hyponatremia focuses on two steps: (1) documentation of the presence and assessment of the severity of symptoms (e.g., acute, chronic) and (2) determination of the most appropriate treatment in relation to the patient's volume status (i.e., hypovolemic, euvolemic, hypervolemic).
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Calculation of sodium deficit. Calculation of the sodium deficit in hyponatremia and the change in serum sodium concentration after infusion of sodium chloride solutions are shown in Appendix C. 84 Many clinicians use an adjusted body weight for electrolyte dosing in obese patients (i.e., patients whose actual weight exceeds 130% of their ideal body weight or who have a body mass index of ≥30 kg/m 2 ). 84 Suggested correction rates are no more than 0.5 meq/L/hr for patients with chronic hyponatremia or hyponatremia of unknown duration, and no more than 1-2 meq/L/hr for patients with severe acute hyponatremia or symptomatic hyponatremia.
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Conventional treatments. Conventional treatment of hyponatremia includes fluid restriction and administration of hypertonic saline and pharmacologic agents such as demeclocycline, lithium carbonate, and urea. 9, 83, [85] [86] [87] [88] Many of these are not approved by the Food and Drug Administration (FDA) for the treatment of hyponatremia and may be limited by variable efficacy, slow onset of action, patient compliance issues, and toxicities. 6, 25 Fluid restriction to <800 mL/day raises serum sodium by only 1-2 meq/L/day, and patient adherence with this treatment is difficult to maintain. In addition, patients re- 84 Conventional pharmacologic agents take several days to achieve maximal effect and can sometimes result in signifi cant toxicities. Demeclocycline, a tetracycline derivative used by some clinicians to assist with the management of hyponatremia, inhibits the antidiuretic effect of AVP on the renal tubules and increases the excretion of solute-free urine, but is associated with a slow onset of action and signifi cant risk of nephrotoxicity. 87 Lithium carbonate is also not appropriate for acute settings and is associated with neurologic adverse effects, cardiotoxicity, and gastrointestinal disturbances. Although effective, urea has poor palatability and is contraindicated in cases of impaired renal function, intracranial bleeding, or liver failure. 6, 89 For patients with severe, acute, symptomatic hyponatremia, hypertonic sodium chloride solution (3%) is used for the correction of the sodium defi cit and may be combined with the diuretic furosemide. 2, 9, 83 Furosemide inhibits sodium and chloride reabsorption in the proximal renal tubules in the loop of Henle and thus increases the volume of tubular fl uid, leading to increased excretion of solute-free water in the distal tubules. 90 For patients with chronic, asymptomatic hyponatremia, water restriction is the fi rst line of treatment. However, some patients fi nd water restriction diffi cult to tolerate, and this can lead to poor patient adherence. 83, 85 Hypertonic sodium chloride solution may also be used as the initial treatment of symptomatic chronic hyponatremia. However, if symptoms resolve or there is a 10% increase of serum sodium levels, water restriction is implemented. 91 Because of the risk of neurologic injury from ODS, sodium correction using hypertonic sodium chloride solution should be administered at a rate of not more than 1-2 meq/L/hr and not more than 12 meq/L per 24 hours or 18 meq/L over the fi rst 48 hours.
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Rate of hyponatremic correction
The correction of hyponatremia (of chronic or indeterminate etiology) should initially occur over 48 hours to minimize the chances of neurologic symptoms of ODS.
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The recommended minimum infusion rate for serum sodium correction, depending on symptoms, is 0.5 meq/L/hr. For those patients with severe symptoms, the recommended correction rate is 1-2 meq/L/hr, with a maximum correction of 25 meq/L achieved over 48 hours. Treatment is generally discontinued if patients' symptoms resolve, if serum sodium concentrations are normalized (≥120 meq/L), or if the maximum correction level over time is reached.
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AVP receptor antagonists
The AVP-receptor antagonists conivaptan, lixivaptan, and tolvaptan are being studied for the treatment of hyponatremia and other indications. Lixivaptan and tolvaptan inhibit the V 2 receptor only, while conivaptan blocks the effects of both V 1a and V 2 receptors. Several studies have found that AVP-receptor antagonists stimulate free-water excretion and improve plasma sodium concentration in patients with hyponatremia. [93] [94] [95] [96] These agents have also been shown to improve hyponatremia in patients with SIADH. 97 Although some studies have shown that V 2 -receptor antagonists may be benefi cial in patients with hyponatremia and liver cirrhosis, 98, 99 conivaptan has not been studied extensively in this setting. In addition, AVP antagonists are not considered appropriate for the treatment of hypovolemic hyponatremia because of the risk of further fl uid depletion.
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Conivaptan. Conivaptan hydrochloride injection has received FDAapproved labeling for the treatment of euvolemic hyponatremia in hospitalized patients. 27 The principal pharmacodynamic effect of conivaptan is the blockade of V 2 receptors in the renal collecting ducts, thus reducing water reabsorption, promoting aquaresis, decreasing urine osmolality, and increasing plasma sodium concentration. [100] [101] [102] In patients with hypervolemic or euvolemic hyponatremia who received an initial i.v. infusion of conivaptan (20 mg infused over 30 minutes) followed by an infusion of 40 mg/day for four days, the maximum serum concentration (C max ) of 781 ng/mL occurred at the conclusion of the loading dose. The median plasma conivaptan concentration at the end of the infusion was 228 ng/mL. The elimination half-life after termination of the infusion was approximately nine hours, and the rate of clearance was 9.5 L/hr. 27 Effi cacy. The effi cacy of conivaptan for the treatment of hyponatremia has been evaluated in several double-blind, placebo-controlled clinical trials. The effects of conivaptan on serum sodium concentration were examined at i.v. doses of 40 or 80 mg/day via continuous infusion in one i.v. and two oral studies. 103 In all three studies, patients had euvolemic or hypervolemic hyponatremia with mean baseline serum sodium values of 124-126 meq/L. In the i.v. conivaptan study, patients who received conivaptan exhibited mean improvements in serum sodium of 6.8 meq/L with the 40-mg dose (p = 0.0001) and 9.0 meq/L with the 80-mg dose (p = 0.0001). After four days, patients administered placebo exhibited a mean improvement in serum sodium of 2.0 meq/L. 103 In other analyses, conivaptan given as a 20-mg i.v. bolus dose followed by a 40-or an 80-mg/day infusion for four days improved the mean change in the total amount of serum sodium (area under the curse [AUC]) to day 4 (p < 0.001 versus placebo) and increased effective water clearance (aquaresis) on day 1 (p < 0.05 versus placebo) in patients with hyponatremia.
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Drug-drug interactions and adverse events. Conivaptan is a substrate of cytochrome P-450 (CYP) 3A4, and coadministration of conivaptan with CYP3A4 inhibitors could lead to an increase in conivaptan concentrations with unknown effects. 27 As a result, concomitant use of conivaptan with potent CYP3A4 inhibitors such as ketoconazole, itraconazole, clarithromycin, ritonavir, and indinavir is contraindicated. 27 As a potent inhibitor of CYP3A4, conivaptan use should be closely monitored (or avoided) if administered concomitantly with drugs that are primarily metabolized by CYP3A4.
In clinical trials of oral conivaptan, digoxin was coadministered, which resulted in a reduction in conivaptan clearance and an increase in digoxin C max and AUC values. If conivaptan is coadministered with digoxin, clinicians should be aware of the possibility of increases in digoxin levels. 27 Concomitant administration of conivaptan (oral formulation) with warfarin, captopril, or furosemide was investigated, and no effects on the pharmacodynamic or pharmacokinetic properties of conivaptan were observed during coadministration with these agents. 27 Intravenous conivaptan has not been studied in patients with hepatic or renal impairment; however, oral conivaptan resulted in increased systemic exposures of the study drug and metabolites for extended periods of time in patients with stable cirrhosis and moderate hepatic impairment. In patients with renal impairment, the AUC for oral conivaptan was up to 80% higher than in patients with normal renal function. Caution should be exercised when administering i.v. conivaptan to patients with impaired hepatic or renal function. 27 Intravenous conivaptan is contraindicated in patients with hypovolemic hyponatremia, and the safety of i.v. conivaptan has not been studied in patients with underlying CHF. 27 The most common adverse event (AE) in clinical studies of i.v. conivaptan has been injection-site reactions (reported in 52.5% of patients and healthy volunteers who received conivaptan 40 mg/day and 3.3% of patients who received placebo). These reactions were generally mild and did not lead to treatment discontinuation; however, conivaptan administration via large veins is recommended, and a change of infusion site every 24 hours will minimize the possible risk of inflammatory response. In an analysis of 72 healthy volunteers and 111 patients with euvolemic hyponatremia administered i.v. conivaptan, AEs included headache, thirst, and hypokalemia. 27 The AE profile in clinical studies of geriatric patients (≥65 and ≤75 years of age) was found to be similar to that seen in the general study populations. 27 Preparation and dosing. As an i.v. agent, conivaptan is compatible with 5% dextrose and is stable for up to 24 hours after mixing. Conivaptan should not be administered with lactated Ringers injection or 0.9% sodium chloride injection. Also, the drug should be administered immediately after dilution and the infusion completed within 24 hours. A loading dose of 20 mg i.v. administered over 30 minutes should be followed by a continuous infusion of 20 mg/day for one to three days.
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Lixivaptan. The orally active V 2 -receptor antagonist lixivaptan has entered Phase III clinical trials. 106 Clinical trials. A Phase I trial investigated the pharmacokinetic and pharmacodynamic properties of lixivaptan in 10 healthy male participants in a dose range from 1 to 500 mg. 107 Increases in C max and AUC were dose-proportional in the range of 50-500 mg. Mean half-life (t ½ ) values were 8-10 hours. Increases in 24-hour urine output and freewater clearance and decreases in urine osmolality were dose-related and statistically significant. 107 Lixivaptan was examined in a study of 60 patients with cirrhosis and dilutional hyponatremia. 99 The primary endpoint was normalization (≥136 mmol/L) of serum sodium, which was achieved by 27% and 50% of patients who received oral lixivaptan at doses of 100 (p < 0.05) and 200 mg/day (p < 0.001), respectively, over 7 days or until the primary endpoint was achieved. The mean time to normalization of serum sodium was 4.8 days (200-mg group) or 5.7 days (100-mg group). Normal serum sodium level was reached by none of the placebo-treated patients. 99 In a study of 44 patients with SIADH, cirrhosis, or CHF, patients were randomized to treatment with placebo or one of three lixivaptan doses (25, 125 , or 250 mg twice daily). 108 Lixivaptan produced a doserelated increase in free-water clearance, serum sodium content, and serum osmolality. The serum sodium level was significantly greater with all three lixivaptan doses than with placebo beginning on the first day of treatment and continuing through the end of day 7 (p < 0.05). 108 AEs. In the lixivaptan study of 60 patients with cirrhosis and dilutional hyponatremia, the most common AEs were gastrointestinal bleeding (1 of 20 patients in the placebo group, 3 of 22 patients in the lixivaptan 100-mg group, and 1 of 18 patients in the lixivaptan 200-mg group) and an increase in serum creatinine to >200 µmol/L during treatment (2 patients in each group). 99 Patient ratings of thirst, assessed on a 100-point rating scale (0 = not thirsty at all; 100 = very thirsty), increased over the study for patients in the lixivaptan 200-mg group but for none of the others. At the end of the study, mean thirst scores were 65, 49, and 49 for the lixivaptan 200-mg, lixivaptan 100-mg, and placebo groups, respectively. The increase in thirst score from baseline was statistically signifi cant in the 200-mg group (p = 0.01) only. 99 In the study of 44 patients with SIADH, cirrhosis, or CHF, thirst was consistently reported by patients in the lixivaptan 250-mg group. 108 Treatment suspension because of excessive sodium elevation (>8 mmol/L or to a serum sodium concentration of >142 mmol/L) was reported for no patients in the placebo group, 1 patient in the lixivaptan 25-mg group, 1 patient in the 125-mg group, and 5 patients in the 250-mg group.
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Tolvaptan. Tolvaptan, an orally active V 2 -receptor antagonist, is now undergoing Phase III clinical trials and is being investigated as an aquaretic agent in advanced heart failure syndromes. 109 Clinical trials. Tolvaptan has been shown in clinical trials of healthy volunteers to exhibit linear pharmacokinetics in oral dosages ranging from 30 to 90 mg/day for 25 to 60 days. Tolvaptan exhibited a time to C max of two to three hours; C max concentrations for single oral dosing in healthy participants were 374 ng/mL (30-mg dose) and 418 ng/mL (90-mg dose). A t ½ was approximately six to eight hours. 109 Tolvaptan has also been shown to increase urine output and serum sodium levels and to improve edema following oral administration of 30-90 mg/day in patients with chronic heart failure, volume overload, and hyponatremia. [93] [94] [95] 110 The effects of tolvaptan were investigated in the Acute and Chronic Therapeutic Impact of Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) study, a large multicenter trial (n = 320) examining patients who experienced New York Heart Association (NYHA) Class III or IV heart failure at screening, left ventricular ejection fraction of <40% during the previous 12 months, and at least two signs of heart failure (e.g., radiographic appearance of congestion on chest x-ray, rales). 111 For the hospitalized patients, oral tolvaptan was administered in 30-, 60-, or 90-mg doses and patients were weighed (postvoid) before dosing and at 24 hours. In the seven-week, outpatient phase of the study, patients continued tolvaptan therapy, with clinical worsening of heart failure as the primary outcome. 111 In the hospitalized patients, median weight loss at approximately 24 hours was 1.8 kg (30 mg), 2.1 kg (60 mg), and 2.8 kg (90 mg) versus 0.6 kg for placebo (p ≤ 0.008 for all doses versus placebo). 96 In the outpatient phase of the study, it was also reported that the primary endpoint of worsening heart failure was indistinguishable between tolvaptantreated and placebo-treated patients (p = 0.88); however, 60-day mortality in patients with renal dysfunction and systemic congestion was reduced in the tolvaptan group versus placebo (p = 0.18). 96 It was later reported that the increase in serum sodium level during hospitalization for patients with CHF and hyponatremia was a predictor of an improved mortality rate at 60 days (p < 0.0269). 93 AEs. AEs in the study of patients with chronic heart failure included dry mouth, thirst, increased urinary frequency, dizziness, nausea, and hypotension, although in this study, the incidence of AEs was generally similar in the tolvaptan and placebo groups. [93] [94] [95] 110 In the ACTIV in CHF clinical trial, the most common AEs were thirst, dry mouth, dizziness, nausea, and hypotension. Because of worsening heart failure, 4% (30 mg), 6% (60 mg), 4% (90 mg), and 5% (placebo) of 130 patients discontinued the trial. 96 
Clinical application for pharmacists
Management of hyponatremia in hospitalized patients depends on the duration and magnitude of hyponatremia. Acute hyponatremia develops in less than 48 hours. Severe hyponatremia (serum sodium <120 meq/L) is associated with neurologic symptoms and is a medical emergency. 9, 11 The inhospital stabilization of hyponatremia is followed by posthospitalization continuation of care. Pharmacists can play an important role in a multidisciplinary patient-centered care team to monitor patient outcomes during the posthospitalization phase. 112 Adequate monitoring is important to ensure optimal treatment outcomes and to avoid costly rehospitalization during the fi rst few weeks after discharge. Automated or Internet-based systems enable health care providers to rapidly assess dosages and access treatment guidelines, drug contraindications, warnings, and potential interactions. 113 Involving patients in AE monitoring and reporting can help patients to optimize treatment regimens. Pharmacists may also infl uence the choice of pharmacologic agents for particular patients, often beginning with the i.v. preparation (e.g., i.v. conivaptan) in the hospital and employing the oral agents for out-of-hospital, long-term applications.
Summary
Many medical conditions (e.g., traumatic brain injury, CHF, liver cirrhosis) are associated with the elevation of serum AVP levels, which stimulates excessive renal water reabsorption and can lead to hyponatremia. Hyponatremia can also occur in patients who receive large quantities of hypotonic fl uids, as in those who require irrigation during surgery. Current, conventional treatment options for hyponatremia are often of limited effectiveness or are diffi cult for patients to tolerate. Conivaptan, a dual V 1a /V 2 AVP-receptor antago-Am J Health-Syst Pharm-Vol 64 Feb 1, 2007 nist approved for the treatment of euvolemic hyponatremia, produced prompt and effective aquaresis within one day of administration in clinical trials and significantly improved serum sodium levels in study participants. In the i.v. conivaptan studies, the most significant AE was infusion-site reaction. The V 2 -receptor antagonists tolvaptan and lixivaptan are also being investigated for the treatment of hyponatremia.
Conclusion
Hyponatremia is a serious health condition for which treatment should be carefully performed. As new agents for treating hyponatremia, AVP-receptor antagonists have demonstrated efficacy and safety in clinical trials and may serve as significant improvements in the current treatment options for managing this disorder.
